# US Medical Society Guidelines & Position Statements (2021-2026)

> **Purpose:** Comprehensive catalog of clinical practice guidelines, position statements, and consensus documents from all ABMS-recognized US medical specialty societies, published 2021-2026. Intended for retrieval-augmented generation in emergency medicine clinical decision support.

> **Scope:** Guidelines relevant to acute care, emergency medicine decision-making, and clinical scenarios encountered in the ED. Organized by specialty.

> **Date:** Compiled February 2026. Guidelines are living documents — check society websites for latest versions.

---

# TABLE OF CONTENTS

1. [Emergency Medicine](#emergency-medicine)
2. [Cardiology](#cardiology)
3. [Pulmonary & Critical Care](#pulmonary--critical-care)
4. [Surgery & Trauma](#surgery--trauma)
5. [Neurology & Neurosurgery](#neurology--neurosurgery)
6. [Gastroenterology & Hepatology](#gastroenterology--hepatology)
7. [Infectious Disease](#infectious-disease)
8. [OB/GYN & Maternal-Fetal Medicine](#obgyn--maternal-fetal-medicine)
9. [Pediatrics](#pediatrics)
10. [Psychiatry](#psychiatry)
11. [Nephrology](#nephrology)
12. [Endocrinology & Diabetes](#endocrinology--diabetes)
13. [Hematology](#hematology)
14. [Oncology](#oncology)
15. [Radiology](#radiology)
16. [Orthopedics](#orthopedics)
17. [Urology](#urology)
18. [Dermatology](#dermatology)
19. [Ophthalmology](#ophthalmology)
20. [Otolaryngology (ENT)](#otolaryngology-ent)
21. [Rheumatology](#rheumatology)
22. [Allergy & Immunology](#allergy--immunology)
23. [Anesthesiology](#anesthesiology)
24. [Pain Medicine & Regional Anesthesia](#pain-medicine--regional-anesthesia)
25. [Physical Medicine & Rehabilitation](#physical-medicine--rehabilitation)
26. [Preventive Medicine & Screening](#preventive-medicine--screening)
27. [Family Medicine](#family-medicine)
28. [Internal Medicine](#internal-medicine)
29. [Geriatrics](#geriatrics)
30. [Palliative Care & Hospice](#palliative-care--hospice)
31. [Sports Medicine](#sports-medicine)
32. [Toxicology](#toxicology)
33. [Wilderness Medicine](#wilderness-medicine)
34. [Vascular Surgery](#vascular-surgery)
35. [Thoracic Surgery](#thoracic-surgery)

---

# Emergency Medicine

## ACEP

### ACEP: Management of Patients Requiring Endotracheal Intubation in the ED (2025)

**Scope:** Peri-procedural interventions to reduce peri-intubation hypoxia and hypotension in adult ED patients.

**Key Recommendations:**
- Evidence-based approach to preoxygenation, RSI drug selection, and hemodynamic optimization
- Addresses critical issues in ED airway management

**Clinical Decision Support:** Algorithmic approach to RSI medication selection

**Source URL:** https://www.annemergmed.com/article/S0196-0644(25)00189-1/abstract

---

### ACEP: Outpatient Management of Adults with Asymptomatic Elevated Blood Pressure (2025)

**Scope:** Disposition and follow-up for incidental hypertension discovered in the ED.

**Key Recommendations:**
- Risk stratification for asymptomatic ED hypertension
- Follow-up timing recommendations based on BP severity
- When to initiate treatment vs. defer to outpatient management

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.acepnow.com/article/acep-clinical-policy-on-outpatient-mgmt-of-adults-with-asymptomatic-elevated-blood-pressure/

---

### ACEP: Management of Adult Patients Presenting to the ED with Seizures (2024)

**Scope:** Evaluation and management of new and recurrent seizures in ED adults.

**Key Recommendations:**
- Evidence-based evaluation of first-time seizure presentations
- Management of recurrent seizure presentations
- Indications for neuroimaging and antiseizure medication initiation

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/38906639/

---

## SAEM

### SAEM GRACE-1: Recurrent Low-Risk Chest Pain in the ED (2022-2023)

**Scope:** Evidence-based risk stratification for recurrent, low-risk chest pain presentations.

**Key Recommendations:**
- Eight priority clinical questions with GRADE evidence
- De-escalation strategies for low-risk presentations
- Integration of high-sensitivity troponin pathways

**Clinical Decision Support:** References HEART, EDACS, and troponin pathway algorithms

**Source URL:** https://www.saem.org/publications/grace/grace-1

---

### SAEM GRACE-2: Abdominal Pain in the ED

**Scope:** Patient-centric guideline for ED abdominal pain evaluation and management.

**Key Recommendations:**
- Structured approach to abdominal pain evaluation
- Evidence-based imaging recommendations
- Disposition guidance

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.saem.org/publications/grace/grace-2

---

### SAEM GRACE-4: Alcohol Withdrawal Syndrome in the ED (2024)

**Scope:** Evidence-based management of alcohol withdrawal presentations including phenobarbital protocols and anti-craving medications.

**Key Recommendations:**
- Phenobarbital as alternative to benzodiazepines for AWS management
- Anti-craving medication initiation (naltrexone) from the ED
- Symptom-triggered therapy protocols

**Clinical Decision Support:** CIWA-Ar referenced for severity assessment

**Source URL:** https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.15093

---

### SAEM/AGS: GED Guidelines 2.0 — Delirium in the ED (2025)

**Scope:** GRADE-based clinical practice guideline for delirium recognition and management in geriatric ED patients.

**Key Recommendations:**
- Screening all older ED patients for delirium
- Validated screening tools (4AT, CAM, bCAM)
- Non-pharmacologic prevention strategies
- Minimization of deliriogenic medications

**Clinical Decision Support:** 4AT and CAM-based screening algorithms

**Source URL:** https://onlinelibrary.wiley.com/doi/10.1111/acem.70167

---

# Cardiology

## ACC/AHA

### ACC/AHA/ACEP/SCAI: Acute Coronary Syndromes (2025)

**Scope:** Comprehensive ACS guideline covering STEMI, NSTEMI, and unstable angina management. Joint with ACEP, NAEMSP, and SCAI. Updates 2013 document.

**Key Recommendations:**
- Updated reperfusion timing targets
- High-sensitivity troponin-based diagnostic algorithms
- Antiplatelet and anticoagulation therapy updates
- Criteria for early invasive vs. ischemia-guided strategy

**Clinical Decision Support:** HEART, TIMI, GRACE score integration; troponin pathway algorithms

**Source URL:** https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309

---

### ACC/AHA: Hypertension Living Guideline (2025)

**Scope:** Living guideline for management of high blood pressure in adults.

**Key Recommendations:**
- Updated treatment targets
- Pharmacotherapy selection algorithms
- Resistant hypertension management
- Special populations (pregnancy, CKD, diabetes)

**Clinical Decision Support:** BP target algorithms by comorbidity

**Source URL:** https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356

---

### ACC/AHA: Perioperative Cardiovascular Management (2024)

**Scope:** Preoperative cardiovascular risk assessment and perioperative cardiac management.

**Key Recommendations:**
- Updated RCRI-based risk stratification
- Functional capacity assessment (METs, DASI)
- Perioperative beta-blocker and statin guidance
- Coronary revascularization before non-cardiac surgery

**Clinical Decision Support:** Algorithmic approach using RCRI, DASI, and NSQIP calculator

**Source URL:** https://www.ccjm.org/content/92/4/213

---

### ACC/AHA/ACCP/HRS: Atrial Fibrillation (2023)

**Scope:** Comprehensive AF management — from risk modification to anticoagulation to rhythm/rate control.

**Key Recommendations:**
- Lifestyle/risk-factor modification as first pillar of AF management
- CHA₂DS₂-VASc for stroke risk; DOACs preferred over warfarin
- Early rhythm control strategy for appropriate patients
- Classification updates (paroxysmal, persistent, long-standing persistent, permanent)

**Clinical Decision Support:** CHA₂DS₂-VASc, HAS-BLED scoring integration

**Source URL:** https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193

---

### AHA: CPR and ECC Guidelines (2025)

**Scope:** Updated resuscitation science, BLS/ACLS protocols, and systems of care.

**Key Recommendations:**
- Updated compression-ventilation protocols
- Post-cardiac arrest care algorithms
- Temperature management updates
- ECPR considerations

**Clinical Decision Support:** ACLS algorithms (cardiac arrest, bradycardia, tachycardia, post-ROSC)

**Source URL:** https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines

---

## HRS

### HRS/SCAI: Transcatheter Left Atrial Appendage Occlusion (2025)

**Scope:** Evidence-based guidance on LAAO for stroke prevention in AF patients.

**Key Recommendations:**
- Patient selection criteria for LAAO
- Procedural considerations and imaging requirements
- Post-procedural antithrombotic management

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.heartrhythmjournal.com/article/S1547-5271(25)02508-1/fulltext

---

# Pulmonary & Critical Care

## CHEST/ATS

### ATS/IDSA: Community-Acquired Pneumonia — Focused Update (2025)

**Scope:** Focused update on 4 key questions for adult CAP diagnosis and management.

**Key Recommendations:**
- Updated empiric antibiotic selection
- Severity assessment and site-of-care decisions
- Role of procalcitonin in guiding therapy duration

**Clinical Decision Support:** PSI/PORT, CURB-65, SMART-COP referenced

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/40679934/

---

### ATS: Pulmonary Rehabilitation (2023)

**Scope:** Evidence-based delivery of pulmonary rehabilitation for COPD, ILD, and chronic respiratory disease.

**Key Recommendations:**
- Exercise training as cornerstone
- Duration and setting recommendations
- Post-exacerbation rehabilitation timing

**Clinical Decision Support:** BODE Index, 6MWT referenced

**Source URL:** https://www.atsjournals.org/doi/10.1164/rccm.202306-1066ST

---

## SCCM

### SCCM: Surviving Sepsis Campaign International Guidelines (2021)

**Scope:** Comprehensive adult sepsis bundles and management recommendations. Most recent full version.

**Key Recommendations:**
- 1-hour bundle: lactate, blood cultures, broad-spectrum antibiotics, IV fluids (30 mL/kg for hypotension/lactate ≥4), vasopressors if hypotensive during/after fluids
- Norepinephrine as first-line vasopressor
- Corticosteroids for refractory septic shock
- Lung-protective ventilation for sepsis-associated ARDS
- Balanced crystalloids preferred

**Clinical Decision Support:** qSOFA, SOFA, sepsis bundles with time targets

**Source URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC8486643/

---

### SCCM: Corticosteroids in Sepsis, ARDS, and CAP (2024)

**Scope:** Focused update on corticosteroid use in three major critical illness syndromes.

**Key Recommendations:**
- Hydrocortisone for septic shock not responsive to fluids and vasopressors
- Dexamethasone for moderate-severe ARDS
- Corticosteroids for severe community-acquired pneumonia

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.sccm.org/clinical-resources/guidelines/guidelines/use-of-corticosteroids-in-sepsis-ards-cap

---

### SCCM: Clinical Deterioration Outside ICU (2023-2024)

**Scope:** Recognizing and responding to clinical deterioration on general wards.

**Key Recommendations:**
- Early warning score implementation (NEWS2, MEWS)
- Rapid response team activation criteria
- Structured communication frameworks
- 10 evidence-based statements

**Clinical Decision Support:** NEWS2, MEWS scoring integration

**Source URL:** https://www.sccm.org/clinical-resources/guidelines/guidelines/guidelines-on-recognizing-and-responding-to-clinical-deterioration-outside-the-icu

---

### SCCM: PADIS Guidelines Update (2023-2024)

**Scope:** Prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in ICU.

**Key Recommendations:**
- Light sedation targets (RASS 0 to −2)
- Routine delirium screening (CAM-ICU)
- Early mobilization protocols
- Non-pharmacologic sleep promotion

**Clinical Decision Support:** RASS, CAM-ICU, BPS/CPOT pain scales

**Source URL:** https://www.sccm.org/clinical-resources/guidelines/guidelines/focused-update-padis-guideline

---

# Surgery & Trauma

## ACS

### ACS TQP: Chest Wall Injuries Best Practices (2025)

**Scope:** Evidence-based management of rib fractures and chest wall trauma.

**Key Recommendations:**
- Rib fracture severity assessment and imaging
- Pain management (multimodal, regional anesthesia)
- Indications for surgical stabilization of rib fractures
- Monitoring for pulmonary complications

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.facs.org/media/qdgliayt/2025_tr_bestpracticesguidelines_chest-wall.pdf

---

### ACS TQP: Genitourinary Injuries (2025)

**Scope:** GU trauma evaluation, imaging, and surgical/nonoperative management.

**Key Recommendations:**
- Imaging criteria for suspected GU injury
- Renal injury grading and management (AAST scale)
- Ureteral, bladder, and urethral injury management algorithms

**Clinical Decision Support:** AAST organ injury scales

**Source URL:** https://www.facs.org/media-center/press-releases/2025/acs-releases-new-best-practices-guidelines-for-management-of-genitourinary-injuries/

---

### ACS: Field Triage Guidelines

**Scope:** EMS trauma destination decision-making criteria for field triage.

**Key Recommendations:**
- Physiologic criteria (GCS, SBP, RR)
- Anatomic criteria (penetrating injuries, fractures)
- Mechanism criteria
- Special considerations (age, anticoagulation, pregnancy)

**Clinical Decision Support:** Tiered triage decision algorithm

**Source URL:** https://www.facs.org/quality-programs/trauma/systems/field-triage-guidelines/

---

## EAST

### EAST: Management of Adult Renal Trauma (2023)

**Scope:** Evidence-based recommendations for blunt and penetrating renal injuries.

**Key Recommendations:**
- CT with IV contrast as initial imaging for stable patients
- Non-operative management for low-grade injuries (AAST I-III)
- Indications for angioembolization vs. surgical exploration

**Clinical Decision Support:** AAST renal injury grading scale

**Source URL:** https://www.east.org/education-resources/practice-management-guidelines

---

### EAST: Management of Hemothorax (2024)

**Scope:** Evidence-based management of traumatic hemothorax.

**Key Recommendations:**
- Chest tube size and placement
- Retained hemothorax management
- Indications for VATS vs. thoracotomy
- Massive hemothorax criteria

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.east.org/education-resources/practice-management-guidelines/category/trauma

---

# Neurology & Neurosurgery

## AAN

### AAN: Management of Functional Seizures (2025)

**Scope:** Evidence-based diagnosis and treatment of psychogenic non-epileptic seizures.

**Key Recommendations:**
- Diagnostic approach (video-EEG as gold standard)
- Communication strategies for diagnosis disclosure
- Cognitive behavioral therapy as first-line treatment
- Antiseizure medication taper guidance

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.neurology.org/doi/10.1212/WNL.0000000000214466

---

### AAN/AAP/CNS/SCCM: Brain Death/Death by Neurologic Criteria (2023)

**Scope:** Updated consensus guideline for determination of brain death in adults and children.

**Key Recommendations:**
- Standardized prerequisite checklist before brain death examination
- Clinical examination requirements (bilateral absence of all brainstem reflexes)
- Apnea testing protocol
- Ancillary testing indications
- Minimum observation periods

**Clinical Decision Support:** Standardized brain death determination checklist

**Source URL:** https://www.neurology.org/doi/abs/10.1212/CPJ.0000000000200189

---

### AHA/ASA: Primary Prevention of Stroke (2024)

**Scope:** Comprehensive stroke prevention recommendations across the lifespan.

**Key Recommendations:**
- Hypertension management for stroke prevention
- Anticoagulation for AF (CHA₂DS₂-VASc-guided)
- Carotid disease screening and intervention thresholds
- Lifestyle modification (diet, exercise, smoking cessation)

**Clinical Decision Support:** CHA₂DS₂-VASc, ABCD² score referenced

**Source URL:** https://www.ahajournals.org/doi/10.1161/STR.0000000000000475

---

# Gastroenterology & Hepatology

## AGA/ACG

### ACG: Ulcerative Colitis Update (2025)

**Scope:** Comprehensive update on UC pharmacologic and surgical management.

**Key Recommendations:**
- Biologic therapy positioning (TNF inhibitors, vedolizumab, ustekinumab, JAK inhibitors)
- Treat-to-target strategies with endoscopic and histologic endpoints
- Surgical timing and techniques

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/40701556/

---

### ACG: Management of Crohn's Disease (2025)

**Scope:** Updated evidence-based review and management recommendations for Crohn's disease.

**Key Recommendations:**
- Early biologic therapy for moderate-to-severe disease
- Therapeutic drug monitoring
- Combination therapy strategies
- Surgical indications

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://gi.org/journals-publications/ebgi/zhai_dalal_sep2025/

---

## AASLD

### AASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (2023, Updated 2025)

**Scope:** Assessment and management of MASLD (formerly NAFLD/NASH). Major nomenclature change from NAFLD to MASLD.

**Key Recommendations:**
- FIB-4 as initial non-invasive screening test for fibrosis
- Vibration-controlled transient elastography for further assessment
- Weight loss (≥10% for fibrosis regression)
- Resmetirom (thyroid hormone receptor agonist) for MASH with fibrosis

**Clinical Decision Support:** FIB-4 index calculation, NAFLD fibrosis score

**Source URL:** https://www.aasld.org/practice-guidelines/clinical-assessment-and-management-metabolic-dysfunction-associated-steatotic

---

### AASLD: Management of Hepatocellular Carcinoma

**Scope:** HCC surveillance, diagnosis, and treatment across disease stages.

**Key Recommendations:**
- Ultrasound ± AFP every 6 months for at-risk patients
- LI-RADS classification for diagnostic imaging
- Barcelona Clinic Liver Cancer (BCLC) staging for treatment allocation
- Systemic therapy updates (atezolizumab-bevacizumab, durvalumab-tremelimumab)

**Clinical Decision Support:** BCLC staging, LI-RADS classification, Child-Pugh score, MELD score

**Source URL:** https://www.aasld.org/practice-guidelines/management-hepatocellular-carcinoma

---

# Infectious Disease

## IDSA

### IDSA: Complicated Urinary Tract Infections (2025)

**Scope:** Empiric antibiotic selection for complicated UTIs in adults.

**Key Recommendations:**
- Urine culture before empiric therapy
- Local resistance patterns guide empiric selection
- Duration of therapy by infection type
- Catheter management strategies

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/

---

### IDSA: COVID-19 Treatment and Management (2025 Update)

**Scope:** Updated treatment and management recommendations based on evolving evidence.

**Key Recommendations:**
- Antiviral therapy (nirmatrelvir/ritonavir, remdesivir) for high-risk patients
- Corticosteroid use in hospitalized patients requiring supplemental oxygen
- Anticoagulation recommendations
- Updated variant-specific considerations

**Clinical Decision Support:** Risk stratification for outpatient treatment eligibility

**Source URL:** https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

---

### IDSA: Complicated Intra-Abdominal Infections Update (2024)

**Scope:** Risk assessment and antimicrobial selection for complicated intra-abdominal infections.

**Key Recommendations:**
- Source control as primary intervention
- Empiric antibiotic selection by severity and resistance risk
- Duration of therapy (typically 4 days after adequate source control)

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.idsociety.org/practice-guideline/all-practice-guidelines/

---

# OB/GYN & Maternal-Fetal Medicine

## ACOG

### ACOG: First and Second Stage Labor Management (2024)

**Scope:** Evidence-based definitions for labor arrest and management of dystocia.

**Key Recommendations:**
- Updated labor arrest criteria (6 cm as onset of active phase)
- Oxytocin augmentation protocols
- Indications for cesarean delivery in labor arrest
- Second stage duration considerations

**Clinical Decision Support:** Labor progress algorithms, Bishop Score referenced

**Source URL:** https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2024/01/first-and-second-stage-labor-management

---

### ACOG: Cervical Ripening in Pregnancy (2025)

**Scope:** Methods and evidence for cervical ripening before labor induction.

**Key Recommendations:**
- Pharmacologic methods (misoprostol, dinoprostone)
- Mechanical methods (Foley catheter, Cook balloon)
- Combination approaches
- Contraindications by method

**Clinical Decision Support:** Bishop Score for ripening assessment

**Source URL:** https://www.acog.org/clinical/clinical-guidance

---

## SMFM

### SMFM: Diagnosis and Management of Fetal Growth Restriction (Consult Series #52)

**Scope:** Standardized prenatal diagnosis and management of FGR.

**Key Recommendations:**
- Ultrasound criteria for FGR diagnosis
- Doppler surveillance protocols
- Delivery timing by severity
- Neonatal outcome considerations

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://publications.smfm.org/publications/289-society-for-maternal-fetal-medicine-consult-series-52/

---

### SMFM: Managing Heart Failure in Pregnant and Postpartum Patients (2024-2025)

**Scope:** Diagnosis and management of peripartum heart failure.

**Key Recommendations:**
- Diagnostic criteria for peripartum cardiomyopathy
- Medical therapy modifications during pregnancy/lactation
- Delivery planning and peripartum monitoring
- Postpartum follow-up recommendations

**Clinical Decision Support:** Framingham criteria adapted for pregnancy

**Source URL:** https://www.smfm.org

---

# Pediatrics

## AAP

### AAP: Evaluation and Treatment of Pediatric Obesity (2023)

**Scope:** First comprehensive AAP clinical practice guideline for pediatric obesity. Covers evaluation, behavioral, pharmacologic, and surgical treatment.

**Key Recommendations:**
- Motivational interviewing for all children with overweight/obesity
- Intensive health behavior and lifestyle treatment (IHBLT) as cornerstone
- Pharmacotherapy consideration for ages 12+ with obesity
- Metabolic and bariatric surgery for ages 13+ with severe obesity
- Comorbidity screening (prediabetes, dyslipidemia, MASLD)

**Clinical Decision Support:** BMI percentile classification, comorbidity screening algorithms

**Source URL:** https://publications.aap.org/pediatrics/article/151/2/e2022060640/190443/

---

### AAP: 2025 Preventive Pediatric Health Care (Periodicity Schedule)

**Scope:** Updated well-child visit and screening schedule recommendations.

**Key Recommendations:**
- Updated screening schedules for developmental, behavioral, and physical health
- Depression screening starting at age 12
- Vision and hearing screening intervals
- Immunization schedule alignment

**Clinical Decision Support:** Age-specific screening timeline

**Source URL:** https://publications.aap.org/pediatrics/article/155/5/e2025071066/200933/

---

# Psychiatry

## APA

### APA: Treatment of Borderline Personality Disorder, 2nd Edition (2024)

**Scope:** Updated evidence-based guideline for BPD assessment and treatment.

**Key Recommendations:**
- Dialectical behavior therapy (DBT) as first-line psychotherapy
- Limited role of pharmacotherapy (symptomatic relief only)
- Risk assessment and crisis management
- Treatment setting considerations

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.psychiatry.org/news-room/news-releases/updated-borderline-personality-disorder-guideline

---

### APA: Prevention and Treatment of Delirium (2025)

**Scope:** Comprehensive guideline for delirium prevention, diagnosis, and management in hospitalized adults.

**Key Recommendations:**
- Non-pharmacologic multicomponent prevention (HELP protocol)
- Screening with validated tools (CAM, 4AT)
- Identification and treatment of underlying causes
- Antipsychotic use limited to severe agitation/distress

**Clinical Decision Support:** CAM, 4AT, RASS for assessment

**Source URL:** https://www.psychiatry.org/news-room/news-releases/apa-published-updated-guideline-for-delirium

---

### APA: Treatment of PTSD (2025 Update)

**Scope:** Evidence-based PTSD treatment in adults.

**Key Recommendations:**
- Trauma-focused psychotherapy (CPT, PE, EMDR) as first-line
- SSRI/SNRI as first-line pharmacotherapy
- Combination therapy considerations
- Treatment of comorbid substance use

**Clinical Decision Support:** PCL-5 for symptom monitoring

**Source URL:** https://www.apa.org/ptsd-guideline

---

# Nephrology

## KDIGO

### KDIGO: Chronic Kidney Disease Evaluation and Management (2024)

**Scope:** Comprehensive CKD guideline covering evaluation, risk stratification, and management.

**Key Recommendations:**
- Race-free CKD-EPI 2021 equation for GFR estimation
- GFR and albuminuria risk matrix for prognosis
- SGLT2 inhibitors for CKD with albuminuria (regardless of diabetes status)
- Finerenone for diabetic kidney disease
- BP target <120 mmHg systolic for most CKD patients

**Clinical Decision Support:** CKD-EPI equation, GFR/albuminuria risk matrix, KDIGO heat map

**Source URL:** https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf

---

### KDIGO: Anemia in CKD (2025)

**Scope:** Updated management of anemia in chronic kidney disease.

**Key Recommendations:**
- Iron supplementation before ESA initiation
- Hemoglobin targets (generally 10-11.5 g/dL)
- HIF-PHI (roxadustat, daprodustat) as alternative to ESAs
- Monitoring protocols

**Clinical Decision Support:** Iron indices algorithm, hemoglobin target ranges

**Source URL:** https://kdigo.org/guidelines/

---

### KDIGO: IgA Nephropathy and IgA Vasculitis (2025)

**Scope:** Diagnosis and treatment of IgAN and IgAV.

**Key Recommendations:**
- Supportive care (RAS blockade, SGLT2 inhibitors)
- Targeted-release budesonide for persistent proteinuria
- Immunosuppression for progressive disease
- Monitoring and follow-up protocols

**Clinical Decision Support:** International IgAN Prediction Tool

**Source URL:** https://www.kidney-international.org/article/S0085-2538(25)00279-0/fulltext

---

# Endocrinology & Diabetes

## ADA

### ADA: Standards of Care in Diabetes (2025)

**Scope:** Annual comprehensive diabetes clinical practice recommendations.

**Key Recommendations:**
- Diagnosis criteria (A1C ≥6.5%, FPG ≥126, 2-hr PG ≥200, random glucose ≥200 with symptoms)
- Individualized glycemic targets (generally A1C <7%)
- GLP-1 RA and SGLT2 inhibitors for cardiorenal benefit regardless of A1C
- DKA management protocols
- Inpatient glucose management

**Clinical Decision Support:** DKA severity criteria (ADA), insulin dosing algorithms, A1C-to-estimated average glucose conversion

**Source URL:** https://professional.diabetes.org/standards-of-care

---

## Endocrine Society

### Endocrine Society: Preexisting Diabetes and Pregnancy (2025)

**Scope:** Joint guideline on management of pregestational diabetes during pregnancy.

**Key Recommendations:**
- Preconception counseling and A1C optimization (<6.5%)
- Insulin as preferred pharmacotherapy in pregnancy
- Continuous glucose monitoring recommended
- Fetal surveillance protocols

**Clinical Decision Support:** Trimester-specific glycemic targets

**Source URL:** https://www.endocrine.org/clinical-practice-guidelines/diabetes-mellitus-and-glucose-metabolism

---

## AACE

### AACE: Pharmacologic Management of Adults with Dyslipidemia (2025)

**Scope:** Evidence-based GRADE recommendations for lipid management and cardiovascular risk reduction.

**Key Recommendations:**
- 13 evidence-based recommendations
- Statin intensity based on ASCVD risk
- LDL-C targets by risk category
- Add-on therapy (ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran)

**Clinical Decision Support:** ASCVD risk calculator, LDL-C treatment targets by risk tier

**Source URL:** https://pro.aace.com/clinical-guidance/2025-clinical-practice-guideline-pharmacologic-management-adults-dyslipidemia

---

# Hematology

## ASH

### ASH: Thrombophilia Testing (2023)

**Scope:** When to test for thrombophilia and management implications.

**Key Recommendations:**
- Avoid routine thrombophilia testing for first provoked VTE
- Consider testing for unprovoked VTE in patients where results would change anticoagulation duration
- Antiphospholipid syndrome testing indications
- Specific testing panels by clinical scenario

**Clinical Decision Support:** None — narrative decision framework

**Source URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC10709681/

---

### ASH: VTE Anticoagulation Therapy (Living Guideline)

**Scope:** Optimal anticoagulant management for VTE prevention and treatment.

**Key Recommendations:**
- DOACs preferred over warfarin for most VTE
- Duration of anticoagulation by VTE type and recurrence risk
- Cancer-associated thrombosis (LMWH or DOACs)
- Higher-intensity anticoagulation strategies

**Clinical Decision Support:** Wells DVT/PE scores referenced for initial management

**Source URL:** https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/anticoagulation-therapy

---

## ISTH

### ISTH: Thrombotic Thrombocytopenic Purpura Focused Update (2025)

**Scope:** Updated TTP management guidelines.

**Key Recommendations:**
- PLASMIC score for rapid risk assessment
- Caplacizumab in addition to plasma exchange and immunosuppression
- Monitoring ADAMTS13 activity for relapse prediction
- Rituximab for preventing relapse

**Clinical Decision Support:** PLASMIC score algorithm

**Source URL:** https://www.jthjournal.org/article/S1538-7836(25)00360-5/fulltext

---

### ASH/ISTH: Heparin-Induced Thrombocytopenia Update (2024)

**Scope:** Joint updated guidelines on HIT management.

**Key Recommendations:**
- 4Ts score for pre-test probability
- Immediate cessation of all heparin products
- Non-heparin anticoagulant selection (argatroban, bivalirudin, fondaparinux)
- Duration of therapeutic anticoagulation

**Clinical Decision Support:** 4Ts score for HIT probability

**Source URL:** https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines

---

# Oncology

## ASCO

### ASCO: Stage IV NSCLC Without Driver Alterations — Living Guideline (2025)

**Scope:** Continuously updated guideline for advanced NSCLC systemic therapy.

**Key Recommendations:**
- Immunotherapy-based combinations as first-line for most patients
- PD-L1 expression guides therapy selection
- Role of chemotherapy backbone
- Second-line options

**Clinical Decision Support:** PD-L1 TPS-based treatment algorithm

**Source URL:** https://ascopubs.org/doi/10.1200/JCO-25-01062

---

### ASCO: Integration of Palliative Care into Standard Oncology Care (2024 Update)

**Scope:** Early palliative care integration across cancer diagnoses.

**Key Recommendations:**
- Early palliative care referral (within 8 weeks of diagnosis of advanced cancer)
- Concurrent with disease-directed therapy
- Symptom management and goals-of-care conversations
- Caregiver support

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35656

---

## NCCN

### NCCN: Comprehensive Cancer Guidelines (2025)

**Scope:** Continuously updated evidence-based treatment guidelines for all major cancer types.

**Key Recommendations:**
- Tumor-type-specific treatment algorithms
- Staging-guided management pathways
- Supportive care and survivorship
- Genetic testing and targeted therapy selection

**Clinical Decision Support:** Disease-specific treatment algorithms, staging systems, biomarker-guided decision trees

**Source URL:** https://www.nccn.org/guidelines/category_1

---

# Radiology

## ACR

### ACR: Appropriateness Criteria (2024-2025, Continuously Updated)

**Scope:** Evidence-based imaging guidelines organized by clinical scenario. 2024 release includes shoulder pain, dementia; April 2025 adds 11 new topics; October 2025 adds 19 new topics.

**Key Recommendations:**
- Clinical-scenario-specific imaging recommendations rated "Usually appropriate," "May be appropriate," or "Usually not appropriate"
- Radiation dose information included
- Age and sex-specific recommendations where applicable
- Categories: Breast, Cardiac, GI, Gyn/OB, MSK, Neurologic, Pediatric, Polytrauma, Thoracic, Urologic, Vascular

**Clinical Decision Support:** Appropriateness ratings (1-9 scale) for each imaging modality by clinical scenario

**Source URL:** https://acsearch.acr.org/list

---

### ACR: Manual on Contrast Media (2024)

**Scope:** Contrast media safety, allergic reactions, and adverse event management.

**Key Recommendations:**
- Premedication protocols for contrast allergy
- Contrast-induced nephropathy risk assessment and prevention
- Management of acute contrast reactions
- Gadolinium-based contrast agent safety

**Clinical Decision Support:** Contrast reaction treatment algorithms

**Source URL:** https://www.acr.org/Clinical-Resources/Contrast-Manual

---

# Orthopedics

## AAOS

### AAOS: Management of Rotator Cuff Injuries (2025)

**Scope:** Updated CPG including biologics and optimizing healing for rotator cuff injuries.

**Key Recommendations:**
- Imaging recommendations (initial X-ray, MRI for surgical candidates)
- Non-operative management (PT, NSAIDs, corticosteroid injections)
- Surgical indications and timing
- Postoperative rehabilitation protocols

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://new.aaos.org/globalassets/quality-and-practice-resources/rotator-cuff/rotator-cuff-2025/rotator-cuff-cpg.pdf

---

### AAOS: Management of Acute Compartment Syndrome (2025)

**Scope:** Diagnosis and surgical management of acute compartment syndrome.

**Key Recommendations:**
- Clinical diagnosis criteria (pain out of proportion, pain with passive stretch, tense compartment)
- Compartment pressure measurement indications
- Fasciotomy timing and technique
- Delta pressure threshold (<30 mmHg below diastolic)

**Clinical Decision Support:** Delta pressure calculation (Diastolic BP − Compartment Pressure)

**Source URL:** https://www.aaos.org/quality/quality-programs/clinical-practice-guidelines/

---

### AAOS: Management of Carpal Tunnel Syndrome (2024)

**Scope:** Evidence-based diagnosis and management of CTS.

**Key Recommendations:**
- Electrodiagnostic testing for confirmation
- Conservative management (splinting, corticosteroid injection)
- Surgical release indications
- Postoperative rehabilitation

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.aaos.org/quality/quality-programs/clinical-practice-guidelines/

---

# Urology

## AUA

### AUA: Microhematuria Amendment (2025)

**Scope:** Updated framework for evaluation and follow-up of microscopic hematuria.

**Key Recommendations:**
- Risk stratification (low, intermediate, high risk)
- CT urogram for high-risk patients
- Cystoscopy indications
- Repeat urinalysis and follow-up protocols

**Clinical Decision Support:** Risk stratification algorithm based on age, sex, smoking, RBC count

**Source URL:** https://www.auanet.org/guidelines-and-quality/guidelines/microhematuria

---

### AUA: Idiopathic Overactive Bladder (2024)

**Scope:** Shared decision-making approach to OAB diagnosis and management.

**Key Recommendations:**
- Behavioral therapies as first-line
- Antimuscarinic and beta-3 agonist medications
- Neuromodulation and botulinum toxin for refractory cases

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.auanet.org/guidelines-and-quality/guidelines/idiopathic-overactive-bladder

---

# Dermatology

## AAD

### AAD: Atopic Dermatitis — Phototherapy and Systemic Therapies (Part 6, 2025)

**Scope:** Updated guidance incorporating newer systemic agents for AD.

**Key Recommendations:**
- Dupilumab as first-line biologic for moderate-severe AD
- JAK inhibitors (abrocitinib, upadacitinib) for inadequate response
- Tralokinumab positioning
- Phototherapy (NB-UVB) for widespread disease
- Monitoring protocols for systemic therapy

**Clinical Decision Support:** SCORAD, EASI, IGA scales for severity assessment

**Source URL:** https://www.jaad.org/article/S0190-9622(25)02125-5/fulltext

---

### AAD: Acne Vulgaris (2024)

**Scope:** Evidence-based acne management in adults and adolescents.

**Key Recommendations:**
- Topical retinoids as foundation of therapy
- Combination therapy (retinoid + antimicrobial)
- Isotretinoin for severe/refractory acne
- Hormonal therapy for females
- Antibiotic stewardship in acne

**Clinical Decision Support:** Acne severity grading (mild, moderate, severe)

**Source URL:** https://www.aad.org/member/clinical-quality/guidelines/acne

---

# Ophthalmology

## AAO

### AAO: Age-Related Macular Degeneration PPP (2025)

**Scope:** AMD screening, diagnosis, and management.

**Key Recommendations:**
- Annual dilated exam for at-risk patients
- Anti-VEGF therapy as standard for neovascular AMD
- AREDS2 supplementation for intermediate AMD
- OCT monitoring protocols

**Clinical Decision Support:** AREDS risk calculator

**Source URL:** https://www.aao.org/education/preferred-practice-pattern

---

### AAO: Diabetic Retinopathy PPP (2024)

**Scope:** Screening, staging, and treatment of diabetic retinopathy.

**Key Recommendations:**
- Annual dilated exam for all diabetic patients
- Anti-VEGF for diabetic macular edema
- PRP for proliferative diabetic retinopathy
- A1C and BP optimization

**Clinical Decision Support:** ETDRS severity scale

**Source URL:** https://www.aao.org/education/preferred-practice-pattern/diabetic-retinopathy-ppp

---

# Otolaryngology (ENT)

## AAO-HNS

### AAO-HNS: Adult Sinusitis Update (2025)

**Scope:** Quality improvement and evidence-based management of adult sinusitis.

**Key Recommendations:**
- Diagnostic criteria (symptoms ≥10 days, or double worsening)
- Watchful waiting for mild acute sinusitis
- Amoxicillin-clavulanate as first-line antibiotic
- CT imaging for chronic/recurrent disease
- Surgical referral criteria

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/abs/10.1002/ohn.1344

---

### AAO-HNS: Sudden Hearing Loss Update

**Scope:** Management of sudden sensorineural hearing loss.

**Key Recommendations:**
- MRI to rule out retrocochlear pathology
- Oral corticosteroids as initial treatment
- Intratympanic steroid injection for incomplete recovery
- Audiologic follow-up

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://www.entnet.org/quality-practice/quality-products/clinical-practice-guidelines/sudden-hearing-loss-update/

---

# Rheumatology

## ACR

### ACR: Treatment of Non-Renal Systemic Lupus Erythematosus (2025)

**Scope:** Evidence-based SLE treatment emphasizing treat-to-target strategy.

**Key Recommendations:**
- Hydroxychloroquine as backbone therapy for all SLE patients
- Limiting glucocorticoids (≤5 mg/day prednisone equivalent as maintenance target)
- Early introduction of immunosuppressive therapy (mycophenolate, azathioprine)
- Biologic therapy (belimumab, anifrolumab) for inadequate response

**Clinical Decision Support:** SLEDAI-2K for disease activity monitoring

**Source URL:** https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25690

---

### ACR: Lupus Nephritis Screening and Management (2024)

**Scope:** Screening, treatment, and management of lupus nephritis in adults and children.

**Key Recommendations:**
- Screening urinalysis and creatinine for all SLE patients
- Renal biopsy for suspected lupus nephritis
- Induction with mycophenolate or cyclophosphamide (based on class)
- Maintenance immunosuppression
- Voclosporin or belimumab as add-on therapy

**Clinical Decision Support:** ISN/RPS lupus nephritis classification

**Source URL:** https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25528

---

# Allergy & Immunology

## AAAAI/ACAAI

### AAAAI/ACAAI: Anaphylaxis Practice Parameter Update (2023)

**Scope:** Diagnosis and management of anaphylaxis across practice settings.

**Key Recommendations:**
- Epinephrine IM as first-line treatment (0.01 mg/kg, max 0.5 mg)
- Observation period minimum 4-6 hours after resolution
- Biphasic reaction risk factors
- Epinephrine auto-injector prescribing at discharge
- Allergen identification and avoidance counseling

**Clinical Decision Support:** Anaphylaxis diagnostic criteria (Sampson/WAO)

**Source URL:** https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Allergist%20Resources/Statements%20and%20Practice%20Parameters/Anaphylaxis-in-Practice-2023.pdf

---

# Anesthesiology

## ASA

### ASA: Preoperative Fasting (2023)

**Scope:** Modular update on preoperative fasting guidelines.

**Key Recommendations:**
- Clear liquids permitted until 2 hours before anesthesia
- Clear liquids with carbohydrates may be beneficial
- 6 hours for light meal, 8 hours for heavy/fatty meal
- Breast milk 4 hours, infant formula 6 hours

**Clinical Decision Support:** Fasting timeline table by food/liquid type

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/36629465/

---

### ASA: Management of PONV (2025)

**Scope:** Updated postoperative nausea and vomiting prevention and treatment.

**Key Recommendations:**
- Apfel score for PONV risk stratification
- Multimodal prophylaxis for moderate-high risk
- TIVA (propofol-based) reduces PONV
- 5-HT3 antagonists, dexamethasone, droperidol as prophylactic agents

**Clinical Decision Support:** Apfel simplified risk score (0-4 factors: female, non-smoker, history of PONV, postoperative opioids)

**Source URL:** https://www.asahq.org/standards-and-practice-parameters

---

# Pain Medicine & Regional Anesthesia

## ASRA

### ASRA: Regional Anesthesia in Antithrombotic/Thrombolytic Therapy, 5th Edition (2025)

**Scope:** Hemorrhagic complication risk mitigation for neuraxial/regional anesthesia in anticoagulated patients.

**Key Recommendations:**
- Drug-specific time intervals before and after neuraxial procedures
- Does NOT recommend andexanet alfa for factor Xa inhibitor reversal before procedures
- Catheter management timelines
- Risk-benefit assessment framework

**Clinical Decision Support:** Drug-specific timing tables for neuraxial procedures

**Source URL:** https://rapm.bmj.com/content/early/2025/01/21/rapm-2024-105766

---

# Physical Medicine & Rehabilitation

## AAPM&R

### AAPM&R: Endorsed Guidelines Collection

**Scope:** Curated guidelines endorsed as relevant to physiatry practice.

**Key Recommendations:**
- AAPM&R primarily endorses guidelines from other organizations
- Covers neurologic rehabilitation, musculoskeletal conditions, pain management
- Check full endorsed list for condition-specific guidance

**Clinical Decision Support:** Varies by endorsed guideline

**Source URL:** https://www.aapmr.org/quality-practice/clinical-practice-guidelines

---

# Preventive Medicine & Screening

## USPSTF

### USPSTF: Breast Cancer Screening (2024)

**Scope:** Biennial mammography screening recommendations.

**Key Recommendations:**
- Grade B: Biennial mammography for all women ages 40-74
- New: Lowered starting age from 50 to 40
- Insufficient evidence for screening >74
- Supplemental screening for dense breasts not yet recommended

**Clinical Decision Support:** Age-based screening timeline

**Source URL:** https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening

---

### USPSTF: Osteoporosis Screening (2025)

**Scope:** Screening for osteoporosis to prevent fractures.

**Key Recommendations:**
- All women ≥65: Screen with DXA
- Postmenopausal women <65 at increased risk: Screen with DXA
- FRAX tool for risk assessment
- Insufficient evidence for men

**Clinical Decision Support:** FRAX calculator, T-score interpretation

**Source URL:** https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening

---

# Family Medicine

## AAFP

### AAFP: Hypertension Guideline (2023)

**Scope:** BP management in adults with hypertension.

**Key Recommendations:**
- Treatment target <140/90 mmHg (differs from ACC/AHA <130/80)
- Lifestyle modification as foundation
- First-line: thiazide, ACE inhibitor/ARB, or CCB
- Combination therapy for most patients requiring pharmacotherapy

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC10042574/

---

# Internal Medicine

## ACP

### ACP: Newer Pharmacologic Treatments for Type 2 Diabetes (2024)

**Scope:** Updated recommendations on GLP-1 RA, SGLT2 inhibitors, and newer agents.

**Key Recommendations:**
- SGLT2 inhibitors for T2DM with CKD or heart failure
- GLP-1 RA for T2DM with ASCVD or high risk
- Individualized A1C targets
- Cost and access considerations

**Clinical Decision Support:** Medication selection algorithm by comorbidity

**Source URL:** https://www.acpjournals.org/doi/10.7326/M23-2788

---

### ACP: Low Back Pain (IMPACt-LBP, 2025)

**Scope:** Non-radicular low back pain management.

**Key Recommendations:**
- Non-pharmacologic interventions first (exercise, multidisciplinary rehab)
- NSAIDs as first-line pharmacotherapy
- Muscle relaxants for short-term use
- Avoid routine imaging for acute nonspecific LBP
- Opioids rarely indicated

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://pmc.ncbi.nlm.nih.gov/articles/PMC11950946/

---

# Geriatrics

## AGS

### AGS: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

**Scope:** Updated explicit list of potentially inappropriate medications (PIMs) to avoid in adults ≥65.

**Key Recommendations:**
- Added opioids as delirium risk medications
- Updated anticoagulation recommendations
- Delirium/dementia/Parkinson disease-specific PIMs expanded
- 5 categories: avoid, use with caution, drug-drug interactions, renal dose adjustments, strong anticholinergics

**Clinical Decision Support:** Searchable PIM list by drug and condition

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/37139824/

---

### AGS: Beers Criteria Alternatives List (2024)

**Scope:** Safer prescribing alternatives companion to Beers Criteria.

**Key Recommendations:**
- Preferred alternatives for each PIM category
- Dose adjustments where complete avoidance isn't possible
- Non-pharmacologic alternatives

**Clinical Decision Support:** PIM → safe alternative lookup table

**Source URL:** https://www.americangeriatrics.org/media-center/news/ags-releases-new-beers-criteriar-alternatives-list-support-safer-prescribing

---

# Palliative Care & Hospice

## AAHPM/ASCO

### ASCO/AAHPM: Palliative Care for Patients with Cancer (2024 Update)

**Scope:** Integrated palliative care in oncology practice.

**Key Recommendations:**
- Palliative care referral within 8 weeks of advanced cancer diagnosis
- Symptom assessment at every visit
- Goals-of-care conversations early and revisited regularly
- Caregiver needs assessment
- Hospice referral when life expectancy ≤6 months

**Clinical Decision Support:** ECOG/KPS for functional assessment; PPI, PaP for prognosis

**Source URL:** https://ascopubs.org/doi/10.1200/JCO.24.00542

---

### NCP: Clinical Practice Guidelines for Quality Palliative Care, 4th Edition

**Scope:** Foundational framework for quality palliative care endorsed by AAHPM.

**Key Recommendations:**
- 8 domains of quality palliative care
- Structure and processes of care
- Physical, psychological, social, spiritual, cultural aspects
- Ethical and legal aspects
- Care of the dying patient

**Clinical Decision Support:** None — quality framework

**Source URL:** https://www.nationalcoalitionhpc.org/wp-content/uploads/2020/07/NCHPC-NCPGuidelines_4thED_web_FINAL.pdf

---

# Sports Medicine

## AMSSM

### AMSSM: Concussion in Sport Position Statement (2023 Update)

**Scope:** Updated diagnosis and management of sport-related concussion.

**Key Recommendations:**
- Remove from play immediately if concussion suspected
- Comprehensive multimodal assessment (SCAT6)
- Graduated return-to-sport protocol (minimum 6 steps, ≥24 hrs per step)
- No same-day return to play
- Special considerations for youth athletes

**Clinical Decision Support:** SCAT6 assessment tool, graded return-to-sport protocol

**Source URL:** https://www.amssm.org/amssm-publishes-updated-p-p-245.html

---

# Toxicology

## ACMT

### ACMT/Poison Centers: Acetaminophen Poisoning Consensus (2023)

**Scope:** Practice guideline for acetaminophen overdose management.

**Key Recommendations:**
- Rumack-Matthew nomogram for acute single ingestions
- Modified Delphi consensus on treatment thresholds
- N-acetylcysteine (NAC) protocol updates
- Extended-release and staggered ingestion management
- King's College Criteria for transplant evaluation

**Clinical Decision Support:** Rumack-Matthew nomogram, King's College Criteria

**Source URL:** https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808062

---

### ACMT: Position Statements Collection

**Scope:** Various position statements on toxicology topics.

**Key Statements:**
- Mold-related inhalation exposures (2023/2024)
- Preventing occupational opioid exposure to emergency responders
- Mifepristone/misoprostol are not controlled dangerous substances
- Acetaminophen and autism controversy (2026)

**Clinical Decision Support:** None — position statements

**Source URL:** https://www.acmt.net/statements/

---

# Wilderness Medicine

## WMS

### WMS: Frostbite Prevention and Treatment (2024 Update)

**Scope:** Evidence-based frostbite prevention, field management, and definitive treatment.

**Key Recommendations:**
- Rapid rewarming in 37-39°C water
- IV iloprost within 48 hours for Grade 3-4 frostbite (major update)
- tPA for severe cases within 24 hours
- Tissue demarcation before debridement (usually weeks)
- Prevention strategies for high-altitude and cold environments

**Clinical Decision Support:** Cauchy frostbite grading system (Grade 1-4)

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/38577729/

---

### WMS: Acute Altitude Illness (2024 Update)

**Scope:** Prevention, diagnosis, and treatment of AMS, HACE, and HAPE.

**Key Recommendations:**
- Gradual ascent (≤500m/day above 3000m)
- Acetazolamide for prophylaxis (125mg BID)
- Dexamethasone for HACE treatment
- Nifedipine for HAPE
- Descent as definitive treatment
- Portable hyperbaric chamber (Gamow bag) when descent impossible

**Clinical Decision Support:** Lake Louise AMS Score, HACE/HAPE diagnostic criteria

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/37833187/

---

# Vascular Surgery

## SVS

### ACC/AHA/SVS: Lower Extremity Peripheral Artery Disease (2024)

**Scope:** Comprehensive multispecialty PAD management guideline.

**Key Recommendations:**
- ABI screening for symptomatic patients and high-risk asymptomatic
- Supervised exercise therapy as first-line for claudication
- Cilostazol for claudication symptom relief
- Revascularization criteria (critical limb ischemia, lifestyle-limiting claudication)
- Risk factor modification (statins, antiplatelets, smoking cessation)

**Clinical Decision Support:** ABI interpretation, Rutherford classification, WIfI staging

**Source URL:** https://www.ahajournals.org/doi/10.1161/CIR.0000000000001251

---

### SVS: Intermittent Claudication Focused Update (2025)

**Scope:** Updated claudication management including risk factors and intervention thresholds.

**Key Recommendations:**
- Structured exercise programs
- Updated pharmacotherapy options
- Endovascular vs. surgical intervention criteria
- Long-term surveillance after intervention

**Clinical Decision Support:** Rutherford classification, ABI trends

**Source URL:** https://www.jvascsurg.org/article/S0741-5214(25)01003-1/fulltext

---

# Thoracic Surgery

## STS

### STS: Surgical Treatment of Atrial Fibrillation (2023-2024)

**Scope:** Surgical AF ablation indications, techniques, and outcomes.

**Key Recommendations:**
- Concomitant AF ablation during cardiac surgery (Class I for symptomatic AF)
- Maze IV procedure remains gold standard
- Left atrial appendage management
- Antiarrhythmic drug management perioperatively

**Clinical Decision Support:** CHA₂DS₂-VASc for stroke risk, AF staging

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/38286206/

---

### STS: Oligometastatic NSCLC Surgical Management (2025)

**Scope:** Surgical indications for oligometastatic non-small cell lung cancer.

**Key Recommendations:**
- Multidisciplinary evaluation required
- Local consolidative therapy after systemic therapy response
- Patient selection criteria
- Perioperative systemic therapy integration

**Clinical Decision Support:** None — narrative guidance

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/39797869/

---

### STS: CT Lung Cancer Screening Standards (2025)

**Scope:** Perioperative quality standards for CT lung cancer screening programs.

**Key Recommendations:**
- Shared decision-making requirements
- Lung-RADS reporting standards
- Multidisciplinary nodule evaluation
- Smoking cessation integration

**Clinical Decision Support:** Lung-RADS classification, screening eligibility criteria

**Source URL:** https://pubmed.ncbi.nlm.nih.gov/41633462

---

# SOCIETY GUIDELINE INDEX PAGES

For ongoing updates, the following master index pages contain all guidelines from each society:

| Society | Guidelines Index |
|---------|-----------------|
| ACEP | https://www.acep.org/patient-care/clinical-policies |
| SAEM GRACE | https://www.saem.org/publications/grace |
| ACC/AHA | https://www.acc.org/guidelines |
| HRS | https://www.hrsonline.org/publications-resources/resource-library/hrs-documents/ |
| CHEST | https://www.chestnet.org/guidelines-and-topic-collections |
| ATS | https://site.thoracic.org/clinicians-researchers/clinical-practice-guidelines-statements-reports |
| SCCM | https://sccm.org/clinical-resources/guidelines/guidelines |
| ACS TQP | https://www.facs.org/quality-programs/trauma/quality/best-practices-guidelines/ |
| EAST | https://www.east.org/education-resources/practice-management-guidelines |
| AAN | https://www.aan.com/guidelines/home/allguidelines |
| AGA | https://gastro.org/clinical-guidance/ |
| ACG | https://gi.org/guidelines/ |
| AASLD | https://www.aasld.org/practice-guidelines |
| IDSA | https://www.idsociety.org/practice-guideline/all-practice-guidelines/ |
| ACOG | https://www.acog.org/clinical |
| SMFM | https://publications.smfm.org/ |
| AAP | https://www.aap.org |
| APA | https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines |
| KDIGO | https://kdigo.org/guidelines/ |
| ADA | https://professional.diabetes.org/standards-of-care |
| Endocrine Society | https://www.endocrine.org/clinical-practice-guidelines |
| AACE | https://pro.aace.com/clinical-guidance |
| ASH | https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines |
| ISTH | https://www.isth.org/page/Guidelines |
| ASCO | https://www.asco.org/guidelines |
| NCCN | https://www.nccn.org/guidelines/category_1 |
| ACR (Radiology) | https://acsearch.acr.org/list |
| AAOS | https://www.aaos.org/quality/quality-programs/clinical-practice-guidelines/ |
| AUA | https://www.auanet.org/guidelines-and-quality/guidelines |
| AAD | https://www.aad.org/member/clinical-quality/guidelines |
| AAO | https://www.aao.org/ppp |
| AAO-HNS | https://www.entnet.org/quality-practice/quality-products/clinical-practice-guidelines/ |
| ACR (Rheum) | https://rheumatology.org/clinical-practice-guidelines |
| AAAAI | https://www.aaaai.org/allergist-resources/statements-practice-parameters/practice-parameters-guidelines |
| ASA | https://www.asahq.org/standards-and-practice-parameters |
| ASRA | https://asra.com/guidelines-articles/guidelines |
| AAPM&R | https://www.aapmr.org/quality-practice/clinical-practice-guidelines |
| USPSTF | https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations |
| AAFP | https://www.aafp.org/pubs/afp |
| ACP | https://www.acponline.org/clinical-information/clinical-guidelines-recommendations |
| AGS | https://www.americangeriatrics.org/publications-tools/guidelines-recommendations |
| AAHPM | https://aahpm.org |
| AMSSM | https://www.amssm.org/Publications.php |
| ACMT | https://www.acmt.net/statements/ |
| WMS | https://wms.org/WMS/WMS/Research/WEM/CPG.aspx |
| SVS | https://vascular.org/vascular-specialists/practice-and-quality/clinical-guidelines |
| STS | https://www.sts.org/resources/clinical-decision-making/clinical-practice-documents-and-policies |
